CliffBio
biologic

PAPZIMEOS

zopapogene imadenovec-drba

Loss of exclusivityAugust 2037projected — 12-year biologic exclusivity estimate
CompanyPrecigen →View the full company profile on CliffBio

Drug detail

Brand namePAPZIMEOS
Active ingredientzopapogene imadenovec-drba
Strength5x10^11PARTICLE UNITS
Dosage formFor Injection
RouteSubcutaneous
ModalityBiologic
FDA approvalAugust 2025
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

PAPZIMEOS patent cliff — loss of exclusivity August 2037 | CliffBio